Biotech

All Articles

A better consider Tough Biotech's Fierce 15

.In this particular full week's incident of "The Leading Pipe," our company are actually diving into...

Lilly deals with phase 2 failing of tau-targeting med

.The confetti is actually still soaring from Eli Lilly's party commemorating the commendation of Alz...

Biogen CMO Maha Radhakrishnan signs up with Sofinnova-- Chutes &amp Ladders

.Welcome to today's Chutes &amp Ladders, our summary of notable leadership hirings, shootings and re...

Lykos will certainly inquire FDA to reconsider its selection adhering to turndown of MDMA therapy for post-traumatic stress disorder

.Following an inadequate presenting for Lykos Therapies' MDMA applicant for post-traumatic stress di...

AN 2 fifty percents census, stops stage 3 test after records let down

.AN2 Therapies is re-thinking its own company in action to poor midphase data, pledging to give up h...

Merck pays for $700M for bispecific, spying autoimmune opening as well as odds to test Amgen in cancer cells

.Merck &amp Co. is paying out $700 million in advance to test Amgen in a blood stream cancer market....

Gilead pays for J&ampJ $320M to leave licensing offer for seladelpar

.With Gilead Sciences almost an FDA selection for its liver health condition medication seladelpar, ...

' All hands on deck' at Lilly as peers target obesity market

.Chief executive officer David Ricks may view the business putting together tents at basecamp behind...

Entero laying off staff, moving out of workplace as well as pausing R&ampD

.Bed Liquidators has transformed Entero Rehabs white colored as a piece. The creditor bought Entero ...

Exelixis drops ADC after deciding it's no suit for Tivdak

.Exelixis is actually losing hope on its cells factor (TF)- targeting antibody-drug conjugate after ...